BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 22570553)

  • 1. The changing landscape of opioid prescribing: long-acting and extended-release opioid class-wide Risk Evaluation and Mitigation Strategy.
    Gudin JA
    Ther Clin Risk Manag; 2012; 8():209-17. PubMed ID: 22570553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk Evaluation and Mitigation Strategies (REMS) for extended-release and long-acting opioid analgesics: considerations for palliative care practice.
    Gudin J
    J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):136-43. PubMed ID: 22764852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary care physician opinion survey on FDA opioid risk evaluation and mitigation strategies.
    Slevin KA; Ashburn MA
    J Opioid Manag; 2011; 7(2):109-15. PubMed ID: 21561034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of opioid risk management and review of the classwide REMS for extended-release/long-acting opioids.
    Stanos S
    Phys Sportsmed; 2012 Nov; 40(4):12-20. PubMed ID: 23306411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ER/LA Opioid Analgesics REMS: Overview of Ongoing Assessments of Its Progress and Its Impact on Health Outcomes.
    Cepeda MS; Coplan PM; Kopper NW; Maziere JY; Wedin GP; Wallace LE
    Pain Med; 2017 Jan; 18(1):78-85. PubMed ID: 27373304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Class-wide REMS for extended-release and long-acting opioids: potential impact on pharmacies.
    Matthews ML
    J Am Pharm Assoc (2003); 2013; 53(1):e1-7. PubMed ID: 23636166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. US Food and Drug Administration's Risk Evaluation and Mitigation Strategy for extended-release and long-acting opioids: pros and cons, and a European perspective.
    Mercadante S; Craig D; Giarratano A
    Drugs; 2012 Dec; 72(18):2327-32. PubMed ID: 23116252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Extended-Release/Long-Acting Opioid Prescribing Risk Evaluation and Mitigation Strategy Program by the US Food and Drug Administration: A Review.
    Heyward J; Olson L; Sharfstein JM; Stuart EA; Lurie P; Alexander GC
    JAMA Intern Med; 2020 Feb; 180(2):301-309. PubMed ID: 31886822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in misuse and abuse of prescription opioids following implementation of Extended-Release and Long-Acting Opioid Analgesic Risk Evaluation and Mitigation Strategy.
    Bucher Bartelson B; Le Lait MC; Green JL; Cepeda MS; Coplan PM; Maziere JY; Wedin GP; Dart RC
    Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1061-1070. PubMed ID: 28758289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increase your Confidence in Opioid Prescribing: Marketing Messages in Continuing Medical Education Activities on ER/LA Opioids.
    Goodwin B; Lim HD; Butler J; Paglia D; Dempsey MT; O Connor B; Fugh-Berman A
    Pain Physician; 2021 Aug; 24(5):E529-E538. PubMed ID: 34323440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ER/LA opioid REMS and accredited education: Survey results provide insight into clinical roles, educational needs, and learner preferences.
    Kear C; McKeithen T; Robertson S
    Subst Abus; 2017; 38(2):145-149. PubMed ID: 28418777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary care physician attitudes and perceptions of the impact of FDA-proposed REMS policy on prescription of extended-release and long-acting opioids.
    Salinas GD; Robinson CO; Abdolrasulnia M
    J Pain Res; 2012; 5():363-9. PubMed ID: 23091393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products.
    Rollman JE; Heyward J; Olson L; Lurie P; Sharfstein J; Alexander GC
    JAMA; 2019 Feb; 321(7):676-685. PubMed ID: 30778596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SCOPE of Pain: An Evaluation of an Opioid Risk Evaluation and Mitigation Strategy Continuing Education Program.
    Alford DP; Zisblatt L; Ng P; Hayes SM; Peloquin S; Hardesty I; White JL
    Pain Med; 2016 Jan; 17(1):52-63. PubMed ID: 26304703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended-release/long-acting opioid REMS may fill the need for prescribers' appropriate use education.
    Nicholson SC; Evanyo K; Salinas GD; Roepke N; Burton BS; Susalka D
    J Opioid Manag; 2012; 8(4):212-6. PubMed ID: 22941848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the impact of the extended-release/long-acting opioid an-algesics risk evaluation and mitigation strategies on opioid prescrip-tion volume.
    Divino V; Cepeda MS; Coplan P; Maziere JY; Yuan Y; Wade RL
    J Opioid Manag; 2017; 13(3):157-168. PubMed ID: 28829517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.
    Paulozzi LJ; Strickler GK; Kreiner PW; Koris CM;
    MMWR Surveill Summ; 2015 Oct; 64(9):1-14. PubMed ID: 26469747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Issues and critiques of the forthcoming risk evaluation and mitigation strategy (REMS) for opioids in pain management.
    Peppin JF; Coleman JJ; Kirsh KL
    Issues Law Med; 2011; 27(2):91-119. PubMed ID: 22372206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Responsible, Safe, and Effective Prescription of Opioids for Chronic Non-Cancer Pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines.
    Manchikanti L; Kaye AM; Knezevic NN; McAnally H; Slavin K; Trescot AM; Blank S; Pampati V; Abdi S; Grider JS; Kaye AD; Manchikanti KN; Cordner H; Gharibo CG; Harned ME; Albers SL; Atluri S; Aydin SM; Bakshi S; Barkin RL; Benyamin RM; Boswell MV; Buenaventura RM; Calodney AK; Cedeno DL; Datta S; Deer TR; Fellows B; Galan V; Grami V; Hansen H; Helm Ii S; Justiz R; Koyyalagunta D; Malla Y; Navani A; Nouri KH; Pasupuleti R; Sehgal N; Silverman SM; Simopoulos TT; Singh V; Solanki DR; Staats PS; Vallejo R; Wargo BW; Watanabe A; Hirsch JA
    Pain Physician; 2017 Feb; 20(2S):S3-S92. PubMed ID: 28226332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Candidate metrics for evaluating the impact of prescriber education on the safe use of extended-release/long-acting (ER/LA) opioid analgesics.
    Willy ME; Graham DJ; Racoosin JA; Gill R; Kropp GF; Young J; Yang J; Choi J; MaCurdy TE; Worrall C; Kelman JA
    Pain Med; 2014 Sep; 15(9):1558-68. PubMed ID: 24828968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.